Recommendations for Artificial Intelligence Application in Continued Process Verification: A Journey Toward the Challenges and Benefits of AI in the Biopharmaceutical Industry.

Journal: PDA journal of pharmaceutical science and technology
PMID:

Abstract

This review paper explores the transformative impact of Artificial Intelligence (AI) on Continued Process Verification (CPV) in the biopharmaceutical industry. Originating from the CPV of the Future project, the study investigates the challenges and opportunities associated with integrating AI into CPV, focusing on real-time data analysis and proactive process adjustments. The paper highlights the importance of aligning AI solutions with regulatory standards and offers a set of comprehensive recommendations to bridge the gap between AI's potential and its practical, compliant, and safe application in pharmaceutical manufacturing. Emphasizing transparency, interpretability, and risk management, the research contributes to establishing best practices for AI implementation, ensuring the highest quality pharmaceutical products while meeting regulatory expectations. The conclusions drawn provide valuable insights for navigating the evolving landscape of AI in pharmaceutical manufacturing. This paper serves as a guideline for implementing AI, Machine Learning and Deep Learning models to the pharma industry. Nevertheless, the specific algorithms used in the CPV of the Future are not relevant for our paper (Good Practices), since we have to generalize the process independent of the algorithm.

Authors

  • Mario Stassen
    Department of Life Sciences Innovation, Stassen Pharmaconsult BV, Aerdenhout, The Netherlands; mmhstassen@gmail.com.
  • Catarina S Leitão
    Data Science Department, ValGenesis Portugal, R. Castilho 50 4th Floor, 1250-071 Lisboa, Portugal.
  • Toni Manzano
    Bigfinite, Corcega 301, Barcelona 08008, Spain; and toni.manzano@aizon.ai.
  • Francisco Valero
    Department of Chemical, Biological and Environmental Engineering, School of Engineering, Universitat Autònoma de Barcelona, 08193 Bellaterra (Barcelona), Spain.
  • Benjamin Stevens
    GSK, 1250 S. Collegeville Road, Collegeville, PA 19426, USA.
  • Matt Schmucki
    Vertex Pharmaceuticals, Cincinnati, OH, USA.
  • David Hubmayr
    Process Development & Breakthrough Technologies R&D, CSL Behring AG, Wankdorfstrasse 10, 3014 Bern, Switzerland.
  • Ferran Mirabent Rubinat
    Aizon, Carrer de Còrsega 301, 08008 Barcelona, Spain.
  • Sandrine Dessoy
    Technical Research and Development, GSK, 89 Rue De L'Institut, B-1330 Rixensart, Belgium.
  • Antonio Moreira
    Department of Chemical, Biochemical, and Environmental Engineering, University of Maryland Baltimore County, 1000 Hilltop Circle, Baltimore, MD 21250.